Dyadic's Stock Jumps On COVID-19 Vaccine Development Pact In India

  • Dyadic International Inc DYAI has collaborated with India-based Syngene International Limited to develop a COVID-19 vaccine candidate.
  • The company says that the vaccine can potentially provide protection against the emerging variants and can be manufactured affordably, at an enormous scale, using Dyadic's proprietary C1-cell protein production platform.
  • Dyadic will work with Syngene to develop a vaccine candidate to immunize people against current and future variants of the COVID-19 virus.
  • Price Action: DYAI shares are up 11.9% at $4.33 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareContractsGeneralBriefsCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!